Clinical Practice Guideline
A systematically developed recommendation for healthcare professionals on appropriate treatment for specific clinical conditions. Guidelines from bodies such as NICE (UK), ADA (diabetes), and AHA (cardiology) incorporate evidence from peptide drug trials to recommend their place in treatment algorithms.
Technical Context
Major guidelines relevant to peptide therapeutics: ADA/EASD Consensus Report for T2D management (positions GLP-1 RAs as preferred second-line therapy after metformin, with cardiovascular-benefit emphasis), NICE NG28 (UK T2D management), ESC/EAS Cardiovascular Prevention guidelines (incorporate GLP-1 RA cardiovascular evidence), AGA guidelines for obesity management, NICE CG189 (obesity), NCCN guidelines for multiple myeloma (bortezomib, carfilzomib), Endocrine Society guidelines for acromegaly (somatostatin analogues), AUA/ASCO guidelines for prostate cancer (GnRH agonists/antagonists), and ESHRE guidelines for IVF protocols (GnRH antagonists). Guidelines are developed through systematic evidence review, expert panel deliberation, and external consultation. They are updated as new evidence emerges — GLP-1 RA positioning has advanced significantly in diabetes and cardiovascular guidelines following CVOT results.